论文部分内容阅读
[目的]观察华蟾素持续动脉灌注联合栓塞治疗原发性肝癌的临床疗效。[方法]64例原发性肝癌患者随机分成治疗组(32例)和对照组(32例),治疗组采用经右股动脉穿刺并于大腿内侧皮下留置化疗泵内灌注华蟾素注射液并进行栓塞治疗;对照组仅采用常规右股动脉穿刺插管肝动脉化疗栓塞术。[结果]治疗组和对照组有效率分别为62.5%和61.3%(P>0.05)。治疗后治疗组AFP下降率优于对照组(P<0.05)。[结论]原发性肝癌患者使用华蟾素注射液持续动脉灌注联合栓塞治疗可以有效抑制肿瘤生展,延长生存期,且具有改善肝功能的作用。
[Objective] To observe the clinical effect of continuous cinobufotalin combined with embolization in the treatment of primary liver cancer. [Methods] Sixty-four patients with primary hepatocellular carcinoma were randomly divided into treatment group (32 cases) and control group (32 cases). The treatment group was infused with cinobufacini injection through the right femoral artery and subcutaneously injected with chemical pump The patients in the control group were treated with conventional right femoral artery catheterization and transcatheter arterial chemoembolization. [Results] The effective rates of the treatment group and the control group were 62.5% and 61.3%, respectively (P> 0.05). After treatment, the AFP decline rate of the treatment group was better than that of the control group (P <0.05). [Conclusion] Cinobufacini injection combined with continuous arterial infusion and embolization can effectively inhibit tumor growth, prolong survival, and improve liver function in patients with primary liver cancer.